CF
CTKB icon

Corebridge Financial’s Cytek Biosciences CTKB Stock Holding History

Corebridge Financial’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-61,718
Closed -$247K – 683
2025
Q1 		$247K Sell
61,718
-2,303
-4% -$11.9K ﹤0.01% 1942
2024
Q4 		$415K Sell
64,021
-5,063
-7% -$30.2K ﹤0.01% 1780
2024
Q3 		$383K Sell
69,084
-246
-0.4% -$1.4K ﹤0.01% 1874
2024
Q2 		$387K Buy
+69,330
New +$416K ﹤0.01% 1828

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Corebridge Financial's CTKB Position: Q2 2025 in Review

Corebridge Financial sold out of Cytek Biosciences (CTKB) in Q2 2025, closing a stake of 61,718 shares — an estimated $247K sold.

Corebridge Financial first reported a position in CTKB in Q2 2024 and held it in 4 quarters. The position peaked at $415K in Q4 2024. 158 funds tracked by Wall St. Rank hold CTKB as of Q2 2025.

  • Corebridge Financial reported no remaining Cytek Biosciences position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 61,718 Cytek Biosciences shares in Q2 2025, an estimated $247K.
  • Corebridge Financial first reported a position in Cytek Biosciences in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Cytek Biosciences position peaked at $415K in Q4 2024.
  • 158 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.